Results 111 to 120 of about 424,107 (362)

Programmed cell death disrupts inflammatory tumor microenvironment (TME) and promotes glioblastoma evolution

open access: yesCell Communication and Signaling
Glioblastoma (GBM) is the most common malignant brain tumor and has a dismal prognosis even under the current first-line treatment, with a 5-year survival rate less than 7%.
Tingyu Liang   +6 more
doaj   +1 more source

Advancing Clinical Medicine with Raman Spectroscopy: Current Trends and Future Perspectives

open access: yesAdvanced Photonics Research, EarlyView.
Raman spectroscopy and microscopy may become excellent tools in clinical medicine, including hematology, oncology, infectious diseases, neurology, gastroenterology, reproductive medicine, rheumatology, and cardiovascular research. However, many challenges such as signal interference, standardization issues, and limited clinical application need to be ...
Jiří Bufka   +5 more
wiley   +1 more source

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited [PDF]

open access: yes, 2012
The cellular and molecular mechanisms of tumor angiogenesis and its prospects for anti-angiogenic cancer therapy are major issues in almost all current concepts of both cancer biology and targeted cancer therapy. Currently, (1) sprouting angiogenesis, (2)
Dumont, Daniel J.   +2 more
core   +1 more source

Glucose Deprivation‐Induced Disulfidptosis via the SLC7A11‐INF2 Axis: Pan‐Cancer Prognostic Exploration and Therapeutic Validation

open access: yesAdvanced Science, EarlyView.
Glucose deprivation or GLUT1 inhibition induces disulfidptosis in SLC7A11high ovarian cancer cells by promoting cystine accumulation, NADPH/ATP depletion, and F‐actin disulfide formation. SLC7A11 interacts with INF2 to further increase H₂O₂ levels and impair mitochondrial fission, suppressing cell migration. Targeting the SLC7A11–INF2 axis represents a
Zhenyu Song   +9 more
wiley   +1 more source

A prognostic model for overall survival in recurrent glioma patients treated with bevacizumab-containing therapy

open access: yesDiscover Oncology
Predictive markers and prognostic models are useful for the individualization of cancer treatment. In this study, we sought to identify clinical and molecular factors to predict overall survival in recurrent glioma patients receiving bevacizumab ...
Shanmu Jin   +22 more
doaj   +1 more source

Efficacy of Combined 5-Fluorouracil and Photodynamic Therapy in Glioma Spheroids

open access: yes, 2018
Standard treatment regimens consisting of surgery, radiation and chemotherapy have proven ineffective for the treatment of high-grade gliomas such as glioblastoma multiforme (GBM).
Singh, Karanjit
core   +1 more source

Hypoxia helps glioma to fight therapy [PDF]

open access: yes, 2009
Despite major improvements in the surgical management the prognosis for patients bearing malignant gliomas is still dismal. Malignant gliomas are notoriously resistant to treatment and the survival time of patients is between 3-8 years for low-grade and
Amberger-Murphy, Verena
core   +1 more source

Unraveling the Role of MDK‐SDC4 Interaction in Pancreatic Cancer‐Associated New‐Onset Diabetes by Single‐Cell Transcriptomic Analysis

open access: yesAdvanced Science, EarlyView.
Midkine (MDK) is a mediator of the interaction between pancreatic cancer and beta cells. MDK, which originated from pancreatic ductal adenocarcinoma cells, exerted deleterious effects on paraneoplastic beta cells by binding to the SDC4 receptor on the beta cell surface and subsequently downregulating the Ras signaling pathway, thereby impairing insulin
Zengyu Feng   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy